These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30451084)

  • 1. Long-term outcome of conservative and invasive treatment in patients with hypertrophic obstructive cardiomyopathy.
    Hoedemakers S; Vandenberk B; Liebregts M; Bringmans T; Vriesendorp P; Willems R; Van Cleemput J
    Acta Cardiol; 2019 Jun; 74(3):253-261. PubMed ID: 30451084
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy.
    Vriesendorp PA; Liebregts M; Steggerda RC; Schinkel AF; Willems R; Ten Cate FJ; van Cleemput J; Ten Berg JM; Michels M
    JACC Heart Fail; 2014 Dec; 2(6):630-6. PubMed ID: 25447346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience.
    Steggerda RC; Damman K; Balt JC; Liebregts M; ten Berg JM; van den Berg MP
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1227-34. PubMed ID: 25326737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy.
    Singh K; Qutub M; Carson K; Hibbert B; Glover C
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):107-15. PubMed ID: 26526299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy.
    Liebregts M; Vriesendorp PA; Mahmoodi BK; Schinkel AF; Michels M; ten Berg JM
    JACC Heart Fail; 2015 Nov; 3(11):896-905. PubMed ID: 26454847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment.
    Leonardi RA; Kransdorf EP; Simel DL; Wang A
    Circ Cardiovasc Interv; 2010 Apr; 3(2):97-104. PubMed ID: 20197511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes.
    Kimmelstiel C; Zisa DC; Kuttab JS; Wells S; Udelson JE; Wessler BS; Rastegar H; Kapur NK; Weintraub AR; Maron BJ; Maron MS; Rowin EJ
    Circ Cardiovasc Interv; 2019 Jul; 12(7):e007673. PubMed ID: 31296080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
    Rigopoulos AG; Daci S; Pfeiffer B; Papadopoulou K; Neugebauer A; Seggewiss H
    Clin Res Cardiol; 2016 Nov; 105(11):953-961. PubMed ID: 27270758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J
    Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyopathy.
    Lucon A; Palud L; Pavin D; Donal E; Behar N; Leclercq C; Mabo P; Daubert JC
    Arch Cardiovasc Dis; 2013; 106(6-7):373-81. PubMed ID: 23806305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry.
    Veselka J; Faber L; Liebregts M; Cooper R; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg J; Stables RH; Jensen MK
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28512112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis.
    Osman M; Kheiri B; Osman K; Barbarawi M; Alhamoud H; Alqahtani F; Alkhouli M
    Clin Cardiol; 2019 Jan; 42(1):190-197. PubMed ID: 30421437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].
    Zheng SW; Shi HY; Dai JJ; Chen H; Wu WH; Qiu XB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):294-301. PubMed ID: 32370480
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of long-term outcome after septal myectomy in symptomatic hypertrophic obstructive cardiomyopathy patients with previous alcohol septal ablation and residual obstruction.
    Zhu C; Tang B; Cui H; Wang S; Xiao M; Chen Z; Meng Y; Zhao S; Song Y; Yu Q; Wang S
    J Card Surg; 2019 Jul; 34(7):533-540. PubMed ID: 31111576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Januska J; Krejci J; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg JM; Veselka J
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1134-1143. PubMed ID: 28595881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy?
    Knyshov G; Lazoryshynets V; Rudenko K; Kravchuk B; Beshlyaga V; Zalevsky V; Rasputnyak O; Batsak B
    Interact Cardiovasc Thorac Surg; 2013 Jan; 16(1):5-9. PubMed ID: 23027595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term outcomes of transcoronary ablation of septal hypertrophy compared to surgical myectomy in patients with symptomatic hypertrophic obstructive cardiomyopathy.
    Samardhi H; Walters DL; Raffel C; Rateesh S; Harley C; Burstow D; Pohlner P; Aroney C
    Catheter Cardiovasc Interv; 2014 Feb; 83(2):270-7. PubMed ID: 23873660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Prognosis after Myectomy in Hypertrophic Obstructive Cardiomyopathy with Severe Left Ventricular Hypertrophy.
    An S; Fan C; Yang Y; Hang F; Wang Z; Zhang Y; Zhang J
    Cardiology; 2018; 139(2):83-89. PubMed ID: 29301125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.